|1.||Farina, C: 2 articles (01/2001 - 07/2000)|
|2.||Gowen, M: 2 articles (01/2001 - 07/2000)|
|3.||Visentin, L: 2 articles (01/2001 - 07/2000)|
|4.||Price, Paul A: 1 article (09/2002)|
|5.||June, Helen H: 1 article (09/2002)|
|6.||Buckley, Jessica R: 1 article (09/2002)|
|7.||Williamson, Matthew K: 1 article (09/2002)|
|8.||Morvan, M: 1 article (01/2001)|
|9.||Belfiore, P: 1 article (01/2001)|
|10.||Nadler, G: 1 article (01/2001)|
|1.||Hypercalcemia (Milk Alkali Syndrome)
07/01/2000 - "SB 242784 completely prevented retinoid-induced hypercalcemia in thyroparathyroidectomized (TPTX) rats when administered orally at 10 mg/kg. SB 242784 was highly efficacious in the prevention of ovariectomy-induced bone loss in the rat when administered orally for 6 months at 10 mg/kg/d and was partially effective at 5 mg/kg/d. "
09/20/2002 - "Measurement of serum levels of cross-linked N-telopeptides, a specific measure of bone resorption activity, showed that treatment with vitamin D alone produced the expected 2.4-fold increase in bone resorption activity and that concurrent treatment with the 40-mg dose of SB 242784 reduced bone resorption activity to below control levels. "
09/20/2002 - "The present experiments were carried out to further test the hypothesis that arterial calcification is linked to bone resorption by determining whether the selective inhibition of bone resorption with SB 242784, a specific inhibitor of the osteoclastic V-H+-ATPase, will inhibit arterial calcification. "
07/01/2000 - "A potent and selective inhibitor of the osteoclastic V-H(+)-ATPase, (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6, 6-pentamethylpiperidin-4-yl)-2,4-pentadienamide (SB 242784), was evaluated in two animal models of bone resorption. "
01/01/2001 - "The most interesting derivative, SB-242784, was able to inhibit bone resorption by human osteoclasts in vitro and to completely prevent ovariectomy-induced bone loss in rats when administered orally at 10 mg kg(-1) day(-1). "
|1.||Dihydrotachysterol (AT 10)
|2.||Proton-Translocating ATPases (ATPase, H+)